Key facts
- This page summarizes Patrick Lin's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Apr 2024, 16:55.
Patrick Lin - 01 Jan 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)
- Reporting relationship
- Chief Business - Strategy Off
- Issuer ticker
- PCSA
- Reported as of
- 01 Jan 2024
- Net transaction value
- -$1,504
- SEC form
- 4
- Accepted by SEC
- 12 Apr 2024, 16:55:13 UTC
- Prior SEC filing
- 12 Oct 2023
- Next SEC filing
- 01 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Lin filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 12 Apr 2024.
Change
- Previous filing in this sequence was filed on 12 Oct 2023.
- Current net transaction value: -$1,504.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PCSA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,675
- Change %
- +6.1%
- Price
- Shares after
- 29,153
- Date
- 01 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F2
PCSA
transaction
Common Stock
Tax liability
- Transaction value
- $1,504
- Shares
- -539
- Change %
- -1.8%
- Price
- $2.79
- Shares after
- 28,614
- Date
- 01 Jan 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PCSA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,675
- Change %
- -7.7%
- Price
- $0.000000
- Shares after
- 20,132
- Date
- 01 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,675
- Exercise price
- $0.000000
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Distribution of vested restricted shares.
Footnote F2
Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.